Skip to Content
Merck
All Photos(1)

Documents

1078733

USP

Bupropion hydrochloride

United States Pharmacopeia (USP) Reference Standard

Synonym(s):

(±)-1-(3-Chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C13H18ClNO · HCl
CAS Number:
31677-93-7
Molecular Weight:
276.20
MDL number:
MFCD00055209
UNSPSC Code:
41116107
PubChem Substance ID:
329749161
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

bupropion

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

Cl[H].CC(NC(C)(C)C)C(=O)c1cccc(Cl)c1

InChI

1S/C13H18ClNO.ClH/c1-9(15-13(2,3)4)12(16)10-6-5-7-11(14)8-10;/h5-9,15H,1-4H3;1H

InChI key

HEYVINCGKDONRU-UHFFFAOYSA-N

Gene Information

human ... SLC6A2(6530) , SLC6A3(6531)

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Bupropion hydrochloride USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

Other Notes

Sales restrictions may apply.

related product

Product No.
Description
Pricing

1078744

Bupropion Hydrochloride Related Compound A, United States Pharmacopeia (USP) Reference Standard

1078755

Bupropion Hydrochloride Related Compound B, United States Pharmacopeia (USP) Reference Standard

1078766

Bupropion Hydrochloride Related Compound C, United States Pharmacopeia (USP) Reference Standard

1078799

Bupropion Hydrochloride Related Compound F, United States Pharmacopeia (USP) Reference Standard

1078846

Bupropion hydrobromide, United States Pharmacopeia (USP) Reference Standard

1112299

3-Chlorobenzoic acid, United States Pharmacopeia (USP) Reference Standard

PHR1744

3-Chlorobenzoic acid, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1752

Bupropion Hydrochloride Related Compound A, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1753

Bupropion Hydrochloride Related Compound B, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1755

Bupropion Related Compound F, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1754

Bupropion Related Compound C, Pharmaceutical Secondary Standard; Certified Reference Material

1078857

Bupropion Related Compound G, United States Pharmacopeia (USP) Reference Standard

1117020

Chloropropiophenone, United States Pharmacopeia (USP) Reference Standard

PHR3178

Bupropion Hydrobromide, pharmaceutical secondary standard, certified reference material

Pictograms

Exclamation mark
GHS07

Signal Word

Warning

Hazard Statements

H302

Precautionary Statements

P301 + P312 + P330

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 6

1 of 6

(±)-Hydroxybupropion-D6 solution 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

H-062

(±)-Hydroxybupropion-D6 solution

Supelco

Supelco

PHR1754

Bupropion Related Compound C

(±)-Bupropion-D9 hydrochloride solution 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

B-052

(±)-Bupropion-D9 hydrochloride solution

(±)-Hydroxybupropion solution 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

H-066

(±)-Hydroxybupropion solution

Phenacetin ≥98.0% (HPLC)

Sigma-Aldrich

77440

Phenacetin

Diclofenac sodium salt

Sigma-Aldrich

D6899

Diclofenac sodium salt

Sergios Charntikov et al.
Neuropharmacology, 86, 181-191 (2014-08-01)
Bupropion is an atypical antidepressant that increases long-term quit rates of tobacco smokers. A better understanding of the relation between nicotine and this first-line medication may provide insight into improving treatment. For all experiments, rats first had nicotine (0.4 mg base/kg)
R L Dufresne et al.
Drug intelligence & clinical pharmacy, 18(12), 957-964 (1984-12-01)
Bupropion is a trimethylated monocyclic phenylaminoketone that is an effective antidepressant in humans. It neither is sedating, anticholinergic, nor cardiotoxic. Its mechanism of action may be related to dopamine, but remains uncertain at this time. Clinical trials comparing bupropion 300-750
Marlene P Freeman
The American journal of psychiatry, 171(7), 723-728 (2014-07-02)
Attention deficit hyperactivity disorder (ADHD) has been increasingly recognized and treated in children and adults in recent years. As a result, a growing number of women enter their reproductive years treated with medication for ADHD or are diagnosed and start
S H Preskorn et al.
Pharmacotherapy, 4(1), 20-34 (1984-01-01)
Bupropion hydrochloride is a new antidepressant that differs clinically and pharmacologically from the tricyclic antidepressants and the monoamine oxidase inhibitors. Pharmacokinetically, bupropion is an intermediate-lived drug with a half-life of about 12 hours. Its antidepressant activity in man has been
Theresa M Winhusen et al.
The Journal of clinical psychiatry, 75(4), 336-343 (2013-12-19)
To evaluate the impact of concurrent treatments for substance use disorder and nicotine-dependence for stimulant-dependent patients. A randomized, 10-week trial with follow-up at 3 and 6 months after smoking quit date conducted at 12 substance use disorder treatment programs between
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service